Cost-effectiveness of Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis

James R M Colbourne; Sam T Alhayo; Beeshman Nandakumar; Shoma Barat; Winston Liauwi; David L Morris; Nayef A Alzahrani

doi:10.21873/invivo.12863

Cost-effectiveness of Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis

In Vivo. 2022 May-Jun;36(3):1527-1533. doi: 10.21873/invivo.12863.

Authors

James R M Colbourne¹, Sam T Alhayo², Beeshman Nandakumar², Shoma Barat², Winston Liauwi^{3

4}, David L Morris², Nayef A Alzahrani^{2

5}

Affiliations

¹ Department of Surgery, University of New South Wales, St. George Hospital, Sydney, NSW, Australia; j.rmcolbourne@gmail.com.
² Department of Surgery, University of New South Wales, St. George Hospital, Sydney, NSW, Australia.
³ Cancer Care Centre, St. George Hospital, Sydney, NSW, Australia.
⁴ St. George and Sutherland Clinical School, University of New South Wales, Sydney, NSW, Australia.
⁵ Department of Surgery, National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.

Abstract

Background: Iterative cytoreduction (iCRS) and hyperthermic intraperitoneal chemotherapy is a treatment for recurrence of peritoneal carcinomatosis. There are considerable upfront costs for this approach for which the cost-effectiveness has not been evaluated.

Patients and methods: We used a prospectively maintained database of patients having undergone primary and iterative cytoreduction at St. George Hospital between January 1, 2014, and December 31, 2017, which was linked with financial data. Cost effectiveness and survival outcomes were used to compare primary cytoreduction (pCRS) and iterative cytoreduction (iCRS) in addition to comparison with other treatment modalities.

Results: The average cost per patient in Australian dollars was $69,295 ($14,691-$696,002) and the average cost per life-year was $15,842. There was no difference in cost-effectiveness between those who had undergone pCRS and those who had undergone iCRS. The overall survival was 52.5 months (95% confidence interval=49.7-55.2 months) with no difference in survival between pCRS and iCRS groups. The median length of hospital stay was significantly longer for patients in the pCRS treatment group (25.51 days) when compared to the iCRS treatment group (21.15 days, p=0.034).

Conclusion: iCRS is a cost-effective treatment in the management of recurrent peritoneal carcinomatosis.

Keywords: General surgery; cost of illness; cytoreduction surgical procedures; peritoneal neoplasms; surgical oncology.

MeSH terms

Australia
Cost-Benefit Analysis
Cytoreduction Surgical Procedures
Humans
Hyperthermia, Induced* / adverse effects
Hyperthermic Intraperitoneal Chemotherapy
Peritoneal Neoplasms* / drug therapy